Sucampo Pharmaceuticals Inc. (SCMP) EVP Matthias Alder Sells 150,000 Shares of Stock
Sucampo Pharmaceuticals Inc. (NASDAQ:SCMP) EVP Matthias Alder sold 150,000 shares of the business’s stock in a transaction on Monday, November 28th. The shares were sold at an average price of $16.00, for a total transaction of $2,400,000.00. Following the completion of the transaction, the executive vice president now directly owns 29,449 shares of the company’s stock, valued at approximately $471,184. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.
Shares of Sucampo Pharmaceuticals Inc. (NASDAQ:SCMP) opened at 17.15 on Wednesday. Sucampo Pharmaceuticals Inc. has a one year low of $9.59 and a one year high of $18.75. The company has a market capitalization of $734.33 million, a PE ratio of 57.94 and a beta of 1.62. The stock has a 50 day moving average of $13.49 and a 200-day moving average of $12.15.
Sucampo Pharmaceuticals (NASDAQ:SCMP) last posted its quarterly earnings data on Wednesday, November 9th. The biopharmaceutical company reported $0.28 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.26 by $0.02. Sucampo Pharmaceuticals had a net margin of 6.29% and a return on equity of 44.19%. The company earned $57.90 million during the quarter, compared to analysts’ expectations of $51.30 million. During the same period in the prior year, the company posted $0.16 earnings per share. Sucampo Pharmaceuticals’s revenue for the quarter was up 73.4% compared to the same quarter last year. On average, equities analysts forecast that Sucampo Pharmaceuticals Inc. will post $1.22 earnings per share for the current fiscal year.
Several equities research analysts recently commented on the stock. Maxim Group boosted their price objective on shares of Sucampo Pharmaceuticals from $17.00 to $19.00 and gave the company a “buy” rating in a research report on Tuesday, November 15th. Vetr cut shares of Sucampo Pharmaceuticals from a “strong-buy” rating to a “buy” rating and set a $14.00 price objective on the stock. in a research report on Monday, September 19th. Zacks Investment Research raised shares of Sucampo Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Monday, August 8th. Jefferies Group cut their price objective on shares of Sucampo Pharmaceuticals from $16.00 to $14.00 and set a “hold” rating on the stock in a research report on Thursday, August 4th. Finally, Mizuho boosted their price objective on shares of Sucampo Pharmaceuticals from $13.00 to $16.00 and gave the company a “neutral” rating in a research report on Monday, November 14th. Five equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $17.33.
Several large investors have recently bought and sold shares of SCMP. Zacks Investment Management purchased a new stake in Sucampo Pharmaceuticals during the second quarter valued at $110,000. Boothbay Fund Management LLC purchased a new stake in Sucampo Pharmaceuticals during the first quarter valued at $114,000. Smith Asset Management Group LP boosted its stake in Sucampo Pharmaceuticals by 69.5% in the second quarter. Smith Asset Management Group LP now owns 10,730 shares of the biopharmaceutical company’s stock valued at $118,000 after buying an additional 4,400 shares during the period. Price T Rowe Associates Inc. MD bought a new stake in Sucampo Pharmaceuticals during the third quarter worth approximately $129,000. Finally, Princeton Alpha Management LP bought a new stake in Sucampo Pharmaceuticals during the second quarter worth approximately $138,000. Institutional investors own 41.12% of the company’s stock.
About Sucampo Pharmaceuticals
Sucampo Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on research and development of drugs to treat gastrointestinal, ophthalmic and oncology-based inflammatory disorders. It operates through development and commercialization of pharmaceutical products segment. Its operations are conducted through Sucampo AG, based in Zug, Switzerland, through which the Company conducts certain worldwide and European operations; Sucampo Pharma, LLC, based in Tokyo and Osaka, Japan and R-Tech Ueno, Ltd., based in Kobe, Japan, through which the Company conducts its Asian operations; Sucampo Pharma Americas LLC, based in Rockville, Maryland, through which the Company conducts operations in North and South America, and Sucampo Pharma Europe, Ltd., based in Oxford, the United Kingdom.
Receive News & Stock Ratings for Sucampo Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sucampo Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.